At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Ecopipamdrug
Likely dose
Ecopipam 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ecopipam Treatment of Pathological Gambling
In Brief
A Phase 2 clinical trial evaluating Ecopipam for Pathological Gambling. Completed, enrolled 34 participants across 4 sites.
Detailed Summary
This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPathological Gambling
CountriesUnited States
CollaboratorsPsyadon Pharma
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedOct 2010
Primary CompletionMay 2012
Study CompletionAug 2012
TodayJul 2026
First PostedOct 6, 2010
Enrollment StartOct 1, 2010
Primary CompletionMay 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.7 years ago
Interventions
Ecopipamdrug
50mg tablets